• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of clinexpimmunolLink to Publisher's site
Clin Exp Immunol. Mar 2007; 147(3): 573–579.
PMCID: PMC1810499

Effect of interleukin-4 on vascular endothelial growth factor production in rheumatoid synovial fibroblasts

Abstract

Interleukin (IL)-4 has been demonstrated to have anti-inflammatory and anti-tumour activity. Because aberrant angiogenesis is a significant pathogenic component of tumour growth and chronic inflammation, we investigated the effect of IL-4 on the production of vascular endothelial growth factor (VEGF) by synovial fibroblasts derived from patients with rheumatoid arthritis (RA). Fibroblast-like synoviocytes (FLS) were prepared from synovial tissues of RA and incubated with different concentrations of IL-4 in the presence or absence of transforming growth factor (TGF)-β. VEGF level was measured by enzyme-linked immunosorbent assay and semiquantitative reverse transcription–polymerase chain reaction. Treatment of FLS with IL-4 alone caused a dose-dependent increase in VEGF levels. In contrast, IL-4 exhibited the inhibitory effect on VEGF production when FLS were stimulated with TGF-β. Combined treatment of IL-4 and IL-10 inhibited TGF-β-induced VEGF production in an additive fashion. TGF-β increased the induction of cyclooxygenase-2 mRNA, which was inhibited significantly by the treatment of IL-4. NS-398, a COX-2 inhibitor, inhibited TGF-β-induced VEGF production in a dose-dependent manner. Furthermore, exogenous addition of prostaglandin E2 (PGE2) restored IL-4 inhibition on TGF-β induced VEGF production. Collectively, our results suggest that IL-4 have an anti-angiogenic effect, especially in the inflammatory milieu of RA by inhibiting the VEGF production in synovial fibroblasts.

Keywords: angiogenesis, fibroblast-like synoviocyte, IL-4, rheumatoid arthritis, vascular endothelial growth factor

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by hyperplasia of synovial lining cells, infiltration of mononuclear cells and abundant new vessel formation in the synovium [1]. The inflamed synovial tissues known as pannus invade adjacent cartilages and bone aggressively, and lead eventually to joint destruction in RA patients. Rheumatoid synovial tissues exhibit similar characteristics of tumour cells in uncontrolled growth, invasiveness and exuberant angiogenesis [2]. New vessel formation relieves hypoxia by satisfying the substantial metabolic requirement of growing tissues. On the other hand, angiogenesis may exacerbate synovitis by facilitating growth of the pannus and increasing the recruitment of inflammatory cells into synovium [3].

Vascular endothelial growth factor (VEGF) is a heparin-binding dimeric glycoprotein that acts on endothelial cells to promote proliferation and induce vascular permeability as well [4,5]. VEGF was detected at high levels in serum and synovial fluid of RA patients compared to those of osteoarthritis or normal controls [6,7]. Serum VEGF levels in patients with RA were correlated with levels of erythrocyte sedimentation rate (ESR) and C-reactive protein [8,9]. Cultured synovial cells produce VEGF in response to hypoxia [10,11] and a variety of stimuli such as prostaglandin E2 (PGE2), tumour necrosis factor (TNF)-α, interleukin (IL)-1, IL-6, transforming growth factor (TGF)-β[1014] and CD40 ligand [15]. Recently, we demonstrated that subcutaneous injection of anti-VEGF peptides, dRK6, ameliorated the disease severity of collagen-induced arthritis in mice [16], indicating that the inhibition of VEGF would be a potential therapeutic strategy in RA.

IL-4 is a multi-functional cytokine secreted by T lymphocytes, basophils and mast cells. IL-4 exhibits anti-inflammatory properties by inhibiting the induction of proinflammatory mediators, such as TNF-α and IL-1, from monocytes [1719]. It can also suppress the production of IL-6, leukaemia inhibitory factor (LIF) and granulocyte–macrophage colony-stimulating factor (GM-CSF) PGE2 by RA synovial fibroblasts, while up-regulating IL-1 receptor antagonists and soluble TNF receptor production [2024]. Moreover, Volpert et al. reported that IL-4 had an anti-angiogenic activity by blocking corneal neovascularization induced by basic fibroblast growth factor [25]. However, the effect of IL-4 on VEGF production in rheumatoid synovial fibroblasts has not been reported. Thus, we investigated whether IL-4 could modulate the basal and stimulated production of VEGF from rheumatoid synovial cells.

Materials and methods

Isolation and cultures of fibroblast-like synoviocytes

Cultured synovial cells used in this study were obtained from RA patients who underwent total joint replacement surgery or synovectomy. The synovial tissues were minced into 2–3-mm pieces and incubated for 4 h with 4 mg/ml collagenase (type I; Worthington Biochemical, Freehold, NJ, USA) in Dulbecco's modified Eagle's medium (DMEM) at 37°C in 5% CO2. After digestion, the dissociated cells were then centrifuged at 500 g, resuspended in DMEM supplemented with 10% fetal calf serum (FCS; Life Technologies, Grand Island, NY, USA), 2 mM glutamine, penicillin (100 unit/ml) and streptomycin (100 µg/ml) and plated in 75-cm2 flasks. After overnight incubation, non-adherent cells were removed. Cultures were kept at 37°C in 5% CO2 and culture medium was replaced every 3 days. When cells reached near confluence they were harvested by trypsinization, and one-third of them were resuspended in culture flasks. A homogeneous population of fibroblast-like synoviocytes (FLS) at passages 4–8 was used for this experiment.

Effects of IL-4, TGF-β and PGE2 on VEGF production by synoviocytes

FLS were seeded in 24-well plates at 6 × 104 cells per well in DMEM supplemented with 5% FCS and cultured at 37°C for 24 h. Cells were washed with serum-free DMEM medium and then incubated in serum-free DMEM supplemented with insulin–transferrin–selenium-A (ITSA; Life Technologies) for 48 h until the medium was replaced with fresh DMEM/ITSA. Subsequently, IL-4 (R&D systems, Minneapolis, MN, USA), TGF-β (10 ng/ml; PeproTech, London, UK) or IL-1β (10 ng/ml; Endogen, Woburn, MA, USA) was added to the wells, and the cells were incubated for 24 h. To assess the effect of IL-4 on VEGF production stimulated by TGF-β, FLS was incubated with various concentrations of IL-4 (0·1–50 ng/ml) in the presence of TGF-β (10 ng/ml). In selected wells, to determine whether PGE2 is involved in the IL-4 effect on TGF-β-induced VEGF production, varying concentrations of PGE2 (0·1–10 µM; Sigma-Aldrich, St Louis, MO, USA) was added to the wells at the beginning of culture. After 24 h of incubation (unless otherwise stated), cell-free media were collected and stored at −20°C until assayed. All cultures were set up in triplicate and results are expressed as mean ± s.d.

Determination of VEGF concentration

VEGF in culture supernatants was measured by sandwich enzyme-linked immunosorbent assay (ELISA), as described previously [15]. Ninety-six-well microtitre plates were coated with 100 µl per well of 0·4 µg/ml goat anti-human VEGF165 (R&D systems) buffered with 50 mM of sodium carbonate, pH 9·6. After incubation overnight at 4°C, the plates were blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 h at room temperature. Human recombinant VEGF165 (R&D Systems) or test samples were added to the wells and then incubated for 2 h at room temperature. The plates were incubated with 0·2 µg/ml biotinylated goat anti-human VEGF165 (R&D Systems) at room temperature for 2 h. Peroxidase-labelled extravidin (Sigma-Aldrich), diluted 1 : 1000, was added to react with the plates at room temperature for 1 h. Colour reaction was induced by the addition of 3,3′,5,5′-tetramethylbenzidine (TMB)/H202 substrate solution and was stopped 30 min later by the addition of 1 M phosphoric acid. An automated microplate reader was used to measure the optical density at a wavelength of 450 nm. Between each of these steps, the plates were washed four times with PBS containing 0·1% Tween 20. Human recombinant VEGF165 diluted in culture medium was used as a calibration standard, ranging from 10 to 2000 pg/ml.

Reverse transcription–polymerase chain reaction (RT–PCR) of VEGF and cyclooxygenase (COX)-2 messenger RNA (mRNA)

FLS were cultured with various concentrations of IL-4 in the presence or absence of TGF-β (10 ng/ml). After 6–12 h of culture, RNA was extracted using RNAzol B (Biotecx, Houston, TX, USA) according to the manufacturer's instructions. Five micrograms of total RNA was then reverse-transcribed using an RT system kit (Life Technologies). PCR amplification of cDNA aliquots was performed by adding 2·5 mM dNTPs, 2·5 units Taq DNA polymerase (Takara Shuzo, Shiga, Japan) and 0·25 µM each of sense and anti-sense primers. The reaction was performed in PCR buffer (1·5 mM MgCl2, 50 mM KCl, 10 mM Tris HCl, pH 8·3) in a total volume of 25 µl. The following primers were used: VEGF sense (5′-TCTTGGGTGCATTGGAGCCTC-3′) and anti-sense (5′-AGCTCATCTCTCCTATGTGC-3′), cyclooxygenase-2 (COX-2) sense (5′-GCAGTTGTTCCAGACAA GCA-3′) and anti-sense (5′-CAGGATACAGCTCCACAGCA-3′) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) sense (5′-CGATGCTGGGCGTGAGTAC-3′) and anti-sense (5′-CGTTCAGTCCAGGGATGA CC-3′). Cycling conditions were as follows: 45 s of denaturation at 94°C for VEGF, COX-2 and GAPDH; 1 min of annealing at 55°C for COX-2 and GAPDH and at 62°C for VEGF, followed by 30 s of elongation at 72°C. The PCR rounds were repeated for 25 cycles for VEGF and GAPDH, and 27 cycles for COX-2. PCR products were run on a 1·5% agarose gel and stained with ethidium bromide. Results are expressed as a ratio of VEGF and COX-2 PCR product to GAPDH product.

Statistical analysis

Data are expressed as the mean ± standard deviation (s.d.). The results were analysed using a non-parametric Mann–Whitney U-test. P-values less than 0·05 were considered significant.

Results

Stimulatory effect of IL-4 on VEGF production in unstimulated synovial fibroblasts

To analyse the effect of IL-4 on VEGF production, FLS were incubated with varying concentrations of IL-4. TGF-β and IL-1β were included as positive control for induction of VEGF. After 24 h of culture, supernatants were collected for measurement of VEGF protein. As shown in Fig. 1, basal levels of VEGF were detectable from FLS incubated in medium alone (45 ± 8 pg/ml). TGF-β (10 ng/ml) and IL-1β (10 ng/ml) strongly increased the production of VEGF by 4·5-fold and 2·2-fold over the media alone (the latter data not shown), respectively, as reported previously [15]. Addition of increasing concentrations of IL-4 (0·1–50 ng/ml) increased the VEGF production in a dose-dependent fashion. The production of VEGF by 50 ng/ml of IL-4 (the maximal concentration used in the study) was twofold over the unstimulated FLS.

Fig. 1
Interleukin (IL)-4 increases vascular endothelial growth factor (VEGF) production in unstimulated synovial fibroblast. Fibroblast-like synoviocytes (FLS) were cultured in triplicate for 24 h with transforming growth factor [(TGF)-β; 10 ng/ml] ...

Inhibitory effect of IL-4 on TGF-β induced VEGF production in synovial fibroblasts

In the rheumatoid synovial joints, resident synoviocytes are exposed to several inflammatory mediators, some of which have a potent angiogenic activity [1014]. Thus, it is clinically relevant to investigate the effect of IL-4 on the VEGF production induced by TGF-β, which is found at a high level in the RA joints. As shown in Fig. 2, the addition of IL-4 resulted in the down-regulatory effect on VEGF production in TGF-β-stimulated fibroblasts by contrast to unstimulated fibroblasts. This effect of IL-4 (1–50 ng/ml) was dose-dependent. The inhibitory effect of IL-4 on VEGF production was also noted when FLS was stimulated with 10 ng/ml of IL-1β (38% inhibition at 50 ng/ml of IL-4). We also tested whether IL-10, another T helper type 2 (Th2) anti-inflammatory cytokine, could regulate TGF-β-induced VEGF production by FLS. The results showed that IL-10 (10 ng/ml) also inhibited the VEGF production induced by TGF-β, which was comparable to the same concentration of IL-4. Moreover, simultaneous treatment of IL-4 with IL-10 resulted in an additive effect on the suppression of VEGF production, compared to each cytokine alone (Fig. 3).

Fig. 2
Interleukin (IL)-4 inhibits transforming growth factor (TGF)-β-induced vascular endothelial growth factor (VEGF) production in synovial fibroblast. Fibroblast-like synoviocytes (FLS) were cultured in triplicate for 24 h with TGF-β (10 ...
Fig. 3
Combined effect of interleukin (IL)-10 and IL-4 on transforming growth factor (TGF)-β-induced vascular endothelial growth factor (VEGF) production. Fibroblast-like synoviocytes (FLS) were cultured for 24 h with TGF-β (10 ng/ml). At the ...

Effect of IL-4 on VEGF mRNA expression in FLS

To determine whether IL-4 modulates VEGF expression at the mRNA level, FLS were cultured with IL-4 (1–50 ng/ml) in the presence or absence of TGF-β (10 ng/ml) and the levels of VEGF mRNA were measured by semiquantitative RT–PCR analysis, as described in Materials and methods. Unstimulated FLS exhibited very low levels of VEGF mRNA expression. Addition of IL-4 alone increased VEGF expression in a dose-dependent manner. In contrast, as observed in ELISA data, IL-4 inhibited VEGF mRNA expression induced by TGF-β in a dose-dependent manner (Fig. 4). These findings indicate that modulation of VEGF by IL-4 is regulated predominantly at mRNA level.

Fig. 4
Opposing effect of interleukin (IL)-4 on vascular endothelial growth factor (VEGF) mRNA expression in unstimulated versus stimulated synovial fibroblast. Fibroblast-like synoviocytes (FLS) were cultured for 12 h with increasing doses of IL-4 alone (left ...

IL-4 inhibition on VEGF production is mediated by down-regulation of PGE2

PGE2 is known to be a potent inducer for VEGF production. It has been suggested that IL-4 inhibits PGE2 synthesis in several cells, including rheumatoid synovial cells, peritoneal macrophages and periodontal ligament fibroblasts [2628]. Thus, it is possible that the decrease in VEGF production by IL-4 is mediated by the IL-4 regulation of PGE2. To address this assumption, we measured the expression of COX-2, a key enzyme for PGE2 generation, in FLS stimulated with TGF-β. As shown in Fig. 5a, unstimulated FLS showed a weak expression of COX-2 mRNA, which increased significantly following stimulation of FLS with TGF-β. The addition of IL-4 resulted in the suppression of TGF-β-induced COX-2 mRNA expression in a dose-dependent manner (Fig. 5a). NS-398, a selective COX-2 inhibitor, exhibited a similar inhibitory action on VEGF production to that observed in IL-4 (Fig. 5b). Moreover, exogenous addition of PGE2 to the FLS cultures cancelled the IL-4 inhibition of VEGF production almost completely (Fig. 6), suggesting that PGE2 mediates the inhibitory effect of IL-4 on TGF-β-induced VEGF production.

Fig. 6
Effect of exogenous prostaglandin E2 (PGE2) on interleukin (IL)-4 inhibition of transforming growth factor (TGF)-β-induced vascular endothelial growth factor (VEGF) production. Fibroblast-like synoviocytes (FLS) were cultured for 24 h with TGF-β ...
Fig. 5
(a) Interleukin (IL)-4 inhibits transforming growth factor (TGF)-β-induced cyclooxygenase-2 (COX-2) mRNA expression in synovial fibroblast. Fibroblast-like synoviocytes (FLS) were cultured for 6 h with medium alone or with 10 ng/ml of TGF-β ...

Discussion

In the present study, we observed that IL-4 induced VEGF production in unstimulated synovial fibroblasts. Our data confirm previous reports showing that IL-4 plays an important role in angiogenesis by inducing VEGF release from several cells types [2931]. IL-4 has a mitogenic action for microvascular endothelial cells by enhancing tube formation in a dose-dependent fashion [32,33]. Moreover, IL-4 stimulates angiogenesis in the rat cornea by up-regulating the VCAM-1 release in vascular endothelial cells [34]. However, most of these results are in vitro observations and/or were carried out in the absence of VEGF or basic fibroblast growth factor (bFGF). Therefore, it is unclear whether IL-4 promotes angiogenesis in the in vivo conditions with high VEGF and FGF, such as RA joints.

In contrast to unstimulated FLS, IL-4 exhibited an inhibitory effect on VEGF production when FLS were stimulated with TGF-β (Fig. 2), suggesting that IL-4 plays an anti-angiogenic role in certain physiological conditions. The anti-angiogenic property of IL-4 was also demonstrated in several cancer models with high VEGF expression levels [3538], in which angiogenesis could be stimulated by tumour hypoxia and a resultant increase in angiogenic factors (VEGF, bFGF, etc.). IL-4-expressing tumours had a reduced level of vascularization compared with controls [39]. Furthermore, retroviral delivery of IL-4 into rat C6 cell gliomas leads to the rapid inhibition of tumour growth in situ [38]. Considering that the suppression of tumour growth and metastasis is linked directly to a decrease in neovascularity, the significant regression of lung metastasis by IL-4 in a murine renal cell carcinoma model further supports the anti-angiogenic role of IL-4 [40].

It has been well demonstrated that IL-4 could scarcely be detected in synovial fluids and synovium of RA patients, while TGF-β, a well-known potent inducer of VEGF, is present in high amounts [41]. The intra-articulator injection of the IL-4 gene resulted in a significant reduction of paw swelling, as well as decreased evidence of bone destruction and cartilage in the adjuvant- and collagen-induced arthritis model [42,43]. Recently, Hass et al. demonstrated that IL-4 exhibited the anti-arthritic effect in the rat adjuvant-induced arthritis model by inhibition of angiogenesis [44]. In the present study, we also observed that the inhibitory effect of IL-4 was not restricted to the VEGF production as TGF-β-induced IL-6 production was down-regulated significantly by IL-4 treatment in a dose-dependent manner (data not shown). Considering that IL-6 is potent inducer of VEGF production in synovial fibroblasts, IL-4 may also inhibit the VEGF production indirectly via suppression of IL-6 synthesis. In this context, it can be postulated that the absence of an IL-4 inhibitory effect on VEGF production in RA joints contributes to the increased neoangiogenesis responsible for chronic inflammatory process.

The importance of COX-2 in the regulation of VEGF has been described in several reports. For example, overexpression of COX-2 has been linked to increased VEGF expression in colon cancer cells [45]. Up-regulation of VEGF by cobalt chloride-stimulated hypoxia was mediated by induction of COX-2 in human prostate cancer cell line [46]. Moreover, inhibition of COX-2 activity by genetic ablation decreased tumour and stromal VEGF levels with marked attenuation of angiogenesis and tumour growth [47]. In our results, TGF-β increased the COX-2 (Fig. 5a) and PGE2 production by FLS (data not shown), which is consistent with a previous report [48]. The induction of COX-2 mRNA expression by TGF-β was suppressed dose-dependently by adding IL-4 as well as NS398, a selective COX-2 inhibitor. As well as inhibition by IL-4 on VEGF production, NS-398, which mitigates endogenous eicosanoid production, suppressed TGF-β-induced VEGF expression in a dose-dependent manner (Fig. 5b). Finally, IL-4 inhibition of VEGF production was recovered by the addition of exogenous PGE2 (Fig. 6). Collectively, these findings indicate that inhibitory effect of IL-4 on VEGF production is mediated by suppression of endogenous COX-2 and PGE2.

In summary, we observed the opposing effect of IL-4 on VEGF production in stimulated versus unstimulated synovial fibroblasts; IL-4 increases spontaneous VEGF production while inhibiting TGF-β-stimulated VEGF production by synovial fibroblasts. IL-4 inhibition of TGF-β-stimulated VEGF production is mediated through the suppression of COX-2 and PGE2. Our findings suggest that the beneficial effect of IL-4 in RA could be explained, in part, by inhibition of VEGF in the inflammatory milieu.

Acknowledgments

This work was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (0405-DB01-0104–0006).

References

1. Koch A. Angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 1998;41:951–62. [PubMed]
2. Harris ED., Jr Recent insights into the pathogenesis of the proliferative lesion in rheumatoid arthritis. Arthritis Rheum. 1976;19:68–72. [PubMed]
3. Walsh DA. Angiogenesis and arthritis. Rheumatology (Oxf) 1999;38:103–12. [PubMed]
4. Conn G, Soderman DD, Schaeffer M, Wile M, Hatcher VB, Thomas KA. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc Natl Acad Sci USA. 1990;87:1323–7. [PMC free article] [PubMed]
5. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hypermeability and angiogenesis. Am J Pathol. 1995;146:1029–39. [PMC free article] [PubMed]
6. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol. 1994;152:4149–56. [PubMed]
7. Fava RA, Olsen NJ, Spencer-Green G, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 1994;180:341–6. [PMC free article] [PubMed]
8. Lee SS, Joo YS, Kim WU, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol. 2001;19:321–4. [PubMed]
9. Maeno N, Takei S, Imanaka H, et al. Increased circulating vascular endothelial growth factor is correlated with disease activity in polyarticular juvenile rheumatoid arthritis. J Rheumatol. 1999;26:2244–8. [PubMed]
10. Jackson JR, Minton JAL, Ho ML, Wei N, Winkler JD. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1β J Rheumatol. 1997;24:1253–9. [PubMed]
11. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine [transforming growth factor-beta (TGF-beta) and interleukin (IL)-1]-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol. 1999;115:176–82. [PMC free article] [PubMed]
12. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor (VEGF) by TNFα and IL-1 in rheumatoid arthritis. Arthritis Rheum. 1998;41:1258–65. [PubMed]
13. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372:83–7. [PubMed]
14. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736–41. [PubMed]
15. Cho CS, Cho ML, Min SY, et al. CD40 engagement on synovial fibroblast up-regulates production of vascular endothelial growth factor. J Immunol. 2000;164:5055–61. [PubMed]
16. Yoo SA, Bae DG, Ryoo JW, et al. Arginine-rich anti-vascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol. 2005;1(174):5846–55. [PubMed]
17. Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA. 1989;86:3803–7. [PMC free article] [PubMed]
18. Wong HL, Lotze MT, Wahl LM, Wahl SM. Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function in circulating monocytes. J Immunol. 1992;148:2118–25. [PubMed]
19. Wong HL, Costa GL, Lotze MT, Wahl SM. Interleukin (IL)-4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J Exp Med. 1993;177:775–81. [PMC free article] [PubMed]
20. Suzuki H, Sugiyama E, Tunru IS, et al. Suppressive effect of interleukin-4 (IL-4) on IL-6 production by adherent rheumatoid synovial cells. Clin Immunol Immunopathol. 1993;66:67–72. [PubMed]
21. Dechanet J, Rissoan MC, Banchereau J, Miossec P. Interleukin 4, but not interleukin 10, regulates the production of inflammation mediators by rheumatoid synoviocytes. Cytokine. 1995;7:176–83. [PubMed]
22. Dechanet J, Taupin JL, Chomarat P, et al. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur J Immunol. 1994;24:3222–8. [PubMed]
23. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol. 1995;154:1432–9. [PubMed]
24. Alaaeddine N, Di Battista JA, Pelletier JP, Kiansa K, Cloutier JM, Martel-Pelletier J. Inhibition of tumor necrosis factor alpha-induced prostaglandin E2 production by the antiinflammatory cytokines interleukin-4, interleukin-10, and interleukin-13 in osteoarthritic synovial fibroblasts: distinct targeting in the signaling pathways. Arthritis Rheum. 1999;42:710–8. [PubMed]
25. Volpert OV, Fong T, Koch AE, et al. Inhibition of angiogenesis by interleukin 4. J Exp Med. 1998;188:1039–46. [PMC free article] [PubMed]
26. Borghaei RC, Rawlings PL, Jr, Mochan E. Interleukin-4 suppression of interleukin-1-induced transcription of collagenase (MMP-1) and stromelysin 1 (MMP-3) in human synovial fibroblasts. Arthritis Rheum. 1998;41:1398–406. [PMC free article] [PubMed]
27. Hart PH, Cooper RL, Finlay-Jones JJ. IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages. Immunology. 1991;72:344–9. [PMC free article] [PubMed]
28. Noguchi K, Shitashige M, Watanabe H, Murota S, Ishikawa I. Interleukin-4 and interferon-gamma inhibit prostaglandin production by interleukin-1beta-stimulated human periodontal ligament fibroblasts. Inflammation. 1999;23:1–13. [PubMed]
29. Faffe DS, Flynt L, Bourgeois K, Panettieri RA, Jr, Shore SA. Interleukin-13 and interleukin-4 induce vascular endothelial growth factor release from airway smooth muscle cells: role of vascular endothelial growth factor genotype. Am J Respir Cell Mol Biol. 2006;34:213–8. [PMC free article] [PubMed]
30. Asano-Kato N, Fukagawa K, Okada N, et al. TGF-beta1, IL-1beta, and Th2 cytokines stimulate vascular endothelial growth factor production from conjunctival fibroblasts. Exp Eye Res. 2005;80:555–60. [PubMed]
31. Wen FQ, Liu X, Manda W, et al. TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol. 2003;111:1307–18. [PubMed]
32. Fukushi J, Morisaki T, Shono T, et al. Novel biological functions of interleukin-4: formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem Biophys Res Commun. 1998;250:444–8. [PubMed]
33. Toi M, Harris AL, Bicknell R. Interleukin-4 is a potent mitogen for capillary endothelium. Biochem Biophys Res Commun. 1991;174:1287–93. [PubMed]
34. Fukushi J, Ono M, Morikawa W, Iwamoto Y, Kuwano M. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol. 2000;165:2818–23. [PubMed]
35. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713–6. [PubMed]
36. Yu JS, Wei MX, Chiocca EA, Martuza RL, Tepper RI. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res. 1993;53:3125–8. [PubMed]
37. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57:503–12. [PubMed]
38. Saleh M, Wiegmans A, Malone Q, Stylli SS, Kaye AH. Effect of in situ retroviral interleukin-4 transfer on established intracranial tumors. J Natl Cancer Inst. 1999;91:438–45. [PubMed]
39. Saleh M, Davis ID, Wilks AF. The paracrine role of tumour-derived mIL-4 on tumour-associated endothelium. Int J Cancer. 1997;72:664–72. [PubMed]
40. Hillman GG, Younes E, Visscher D, et al. Systemic treatment with interleukin-4 induces regression pulmonary metastases a murine renal cell carcinoma model. Cell Immunol. 1995;160:257–63. [PubMed]
41. Miossec P, Naviliat M, Dupuy d'Angeac A, Sany J, Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. Arthritis Rheum. 1990;33:1180–7. [PubMed]
42. Boyle DL, Nguyen KH, Zhuang S, et al. Intra-articular IL-4 gene therapy in arthritis: anti-inflammatory effect and enhanced Th2 activity. Gene Ther. 1999;6:1911–18. [PubMed]
43. Lubberts E, Joosten LA, van Den Bersselaar L, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol. 1999;163:4546–56. [PubMed]
44. Haas CS, Amin MA, Allen BB, et al. Inhibition of angiogenesis by interleukin-4 gene therapy in rat adjuvant-induced arthritis. Arthritis Rheum. 2006;54:2402–14. [PubMed]
45. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16. [PubMed]
46. Liu XH, Kirschenbaum A, Yao S, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastasis. 1999;17:687–94. [PubMed]
47. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest. 2000;105:1511–3. [PMC free article] [PubMed]
48. Fong CY, Pang L, Holland E, Knox AJ. TGF-beta1 stimulates IL-8 release, COX-2 expression, and PGE(2) release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2000;279:L201–7. [PubMed]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...